Lantern Pharma
LTRN
25 hedge funds and large institutions have $10.4M invested in Lantern Pharma in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 10 increasing their positions, 6 reducing their positions, and 11 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 6
1.33% less ownership
Funds ownership: 14.81% → 13.48% (-1.3%)
21% less capital invested
Capital invested by funds: $13.1M → $10.4M (-$2.74M)
24% less funds holding
Funds holding: 33 → 25 (-8)
73% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 11
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $21K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SMH
Sanders Morris Harris
Houston,
Texas
|
+$319K |
| 2 |
CC
Carlson Capital
Dallas,
Texas
|
+$282K |
| 3 |
CM
CM Management
Gulf Breeze,
Florida
|
+$225K |
| 4 |
Renaissance Technologies
New York
|
+$71.5K |
| 5 |
JP Morgan Chase
New York
|
+$18.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$519K |
| 2 |
LCM
Lynwood Capital Management
Toronto,
Ontario, Canada
|
-$399K |
| 3 |
Millennium Management
New York
|
-$387K |
| 4 |
Two Sigma Investments
New York
|
-$329K |
| 5 |
Morgan Stanley
New York
|
-$257K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AFM
26
Anson Funds Management
Dallas,
Texas
| – | -$519K | -64,999 | Closed |
|
|
LCM
27
Lynwood Capital Management
Toronto,
Ontario, Canada
| – | -$399K | -50,000 | Closed |
|
|
28
Millennium Management
New York
| – | -$387K | -48,558 | Closed |
|
|
TI
29
Trexquant Investment
Stamford,
Connecticut
| – | -$223K | -27,970 | Closed |
|
30
Two Sigma Advisers
New York
| – | -$202K | -25,300 | Closed |
|
31
Citadel Advisors
Miami,
Florida
| – | -$89K | -11,095 | Closed |
|
|
JF
32
Jump Financial
Chicago,
Illinois
| – | -$88K | -11,028 | Closed |
|
33
Envestnet Asset Management
Chicago,
Illinois
| – | -$84K | -10,542 | Closed |
|
34
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$83K | -10,439 | Closed |
|
35
Bank Julius Baer & Co
Zurich,
Switzerland
| – | -$20K | -2,500 | Closed |
|
LTRN Hedge Fund Activity: Q1 2022 in Review
25 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Lantern Pharma (LTRN) for Q1 2022, worth a combined $10.4M — down 21% from $13.1M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of LTRN and 3 opened new positions — a net loss of 8 holders — while 6 trimmed existing stakes and 10 added.
The largest buyer was Sanders Morris Harris, adding an estimated $319K. The largest seller was Anson Funds Management, exiting entirely with an estimated $519K sold.
- 25 institutional investors held Lantern Pharma (LTRN) as of Q1 2022, down from 33 in Q4 2021.
- Funds reported $10.4M of Lantern Pharma stock for Q1 2022, down 21% quarter-over-quarter.
- 3 funds opened new Lantern Pharma positions in Q1 2022 and 11 closed out, a net change of -8 holders.
- The largest Lantern Pharma buyer in Q1 2022 was Sanders Morris Harris, an estimated $319K added.
- The largest Lantern Pharma seller in Q1 2022 was Anson Funds Management, an estimated $519K sold.
Based on aggregated 13F filings for Q1 2022.